CD226 regulates natural killer cell antitumor responses via phosphorylation-mediated inactivation of transcription factor FOXO1

por Du, Xiangnan, de Almeida, Patricia, Manieri, Nick, de Almeida Nagata, Denise, Wu, Thomas D., Harden Bowles, Kristin, Arumugam, Vidhyalakshmi, Schartner, Jill, Cubas, Rafael, Mittman, Stephanie, Javinal, Vincent, Anderson, Keith R., Warming, Søren, Grogan, Jane L., Chiang, Eugene Y.
Publicado 2018

Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses

por Banta, Karl L., Xu, Xiaozheng, Chitre, Avantika S., Au-Yeung, Amelia, Takahashi, Chikara, O’Gorman, William E., Wu, Thomas D., Mittman, Stephanie, Cubas, Rafael, Comps-Agrar, Laetitia, Fulzele, Amit, Bennett, Eric J., Grogan, Jane L., Hui, Enfu, Chiang, Eugene Y., Mellman, Ira
Publicado 2022

Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors

por Castiglioni, Alessandra, Yang, Yagai, Williams, Katherine, Gogineni, Alvin, Lane, Ryan S., Wang, Amber W., Shyer, Justin A., Zhang, Zhe, Mittman, Stephanie, Gutierrez, Alan, Astarita, Jillian L., Thai, Minh, Hung, Jeffrey, Yang, Yeqing Angela, Pourmohamad, Tony, Himmels, Patricia, De Simone, Marco, Elstrott, Justin, Capietto, Aude-Hélène, Cubas, Rafael, Modrusan, Zora, Sandoval, Wendy, Ziai, James, Gould, Stephen E., Fu, Wenxian, Wang, Yulei, Koerber, James T., Sanjabi, Shomyseh, Mellman, Ira, Turley, Shannon J., Müller, Sören
Publicado 2023